Reuters logo
BRIEF-Nektar Therapeutics says NKTR-181 meets primary, secondary endpoints in Phase 3 summit-07 study in chronic pain
2017年3月20日 / 中午11点49分 / 7 个月前

BRIEF-Nektar Therapeutics says NKTR-181 meets primary, secondary endpoints in Phase 3 summit-07 study in chronic pain

March 20 (Reuters) - Nektar Therapeutics

* Nektar Therapeutics says NKTR-181, an opioid analgesic, meets primary and secondary endpoints in phase 3 summit-07 study in chronic pain

* Nektar therapeutics says NKTR-181 significantly reduced pain in patients with moderate to severe chronic low back pain

* FDA has granted investigational NKTR-181 fast track designation for the treatment of moderate to severe chronic pain Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below